Form 4: Theravance Biopharma Director Acquires Shares and Options in Recent Transaction

Director Susannah Gray reports acquisition of Theravance Biopharma shares and options, signaling potential confidence in the company's future.

Summary

• On May 19, 2025, Susannah Gray, a director of Theravance Biopharma, acquired 10,649 ordinary shares at $0 and disposed of 42,137 shares.
• Following these transactions, Gray directly owns 42,137 ordinary shares.
• Gray also acquired 24,258 share options with an exercise price of $9.39, exercisable from May 19, 2025, and expiring on May 18, 2035.
• These options vest in installments, with 1/12th vesting monthly and the remainder vesting on the next annual shareholder meeting date, contingent on continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director can be seen as a positive sign, but it's a routine transaction disclosure.

Positives

• The acquisition of shares and options by a director may signal confidence in the company's prospects.
• The vesting schedule of the options incentivizes continued service by the director.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company insiders.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates

Keywords

Theravance Biopharma, TBPH, Director, Susannah Gray, Share Acquisition, Share Options, Beneficial Ownership, Form 4